Price T Rowe Associates Inc Lyra Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 17,541 shares of LYRA stock, worth $1,578. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,541
Previous 17,541
-0.0%
Holding current value
$1,578
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LYRA
# of Institutions
57Shares Held
25MCall Options Held
56.6KPut Options Held
33.9K-
Perceptive Advisors LLC New York, NY12.8MShares$1.15 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$254,6980.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.77MShares$158,9020.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA1.39MShares$125,1110.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.06MShares$95,2330.02% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $2.86M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...